JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

Search

Day One Biopharmaceuticals Inc

Closed

SectorHealthcare

7.33 -2.14

Overview

Share price change

24h

Current

Min

7.31

Max

7.46

Key metrics

By Trading Economics

Income

5.7M

-30M

Sales

3.1M

34M

Profit margin

-89.424

Employees

182

EBITDA

5.2M

-35M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+220.43% upside

Dividends

By Dow Jones

Next Earnings

4 Nov 2025

Market Stats

By TradingEconomics

Market Cap

76M

759M

Previous open

9.47

Previous close

7.33

News Sentiment

By Acuity

50%

50%

163 / 373 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Day One Biopharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

27 Oct 2025, 23:32 UTC

Acquisitions, Mergers, Takeovers

CSL Delays Flu-Vaccine Spinoff, Cuts Guidance As U.S. Vaccination Rates Decline

27 Oct 2025, 23:00 UTC

Acquisitions, Mergers, Takeovers

Australia's AUB Opens Books to EQT After Receiving $3.44 Billion Takeover Offer

27 Oct 2025, 21:42 UTC

Earnings

Waste Management 3Q Revenue Climbs, Sees Fiscal Year Revenue at Low End of Prior View

27 Oct 2025, 23:43 UTC

Market Talk

Nikkei May Rise on Easing U.S.-China Trade Tensions -- Market Talk

27 Oct 2025, 23:42 UTC

Market Talk

Gold Rises on Likely Technical Recovery -- Market Talk

27 Oct 2025, 23:37 UTC

Market Talk

Investors May Cheer CSL's Decision to Delay Seqirus Spinoff -- Market Talk

27 Oct 2025, 23:00 UTC

Earnings

The Good Vibes Are Back on Wall Street -- WSJ

27 Oct 2025, 22:45 UTC

Acquisitions, Mergers, Takeovers

Australia's AUB Opens Books to EQT After Receiving $3.44B Takeover Offer

27 Oct 2025, 22:06 UTC

Market Talk
Earnings

Nucor Expects Weaker Steel Market in 4Q -- Market Talk

27 Oct 2025, 22:05 UTC

Earnings

China Southern Airlines: Continued Improvements in Business Environment Supported Results >1055.HK

27 Oct 2025, 22:04 UTC

Earnings

Cadence Reports Solid Earnings. The Stock Is Falling. -- Barrons.com

27 Oct 2025, 22:04 UTC

Earnings

China Southern Airlines 3Q Net CNY3.84B, Up 20.3% on Year >1055.HK

27 Oct 2025, 22:03 UTC

Earnings

China Southern Airlines 3Q Rev CNY51.37B, Up 3.0% on Year >1055.HK

27 Oct 2025, 21:27 UTC

Earnings

Waste Management 3Q Rev Climbs, Sees FY Rev at Low End of Prior View

27 Oct 2025, 21:19 UTC

Earnings

Cadence Reports Solid Earnings. The Stock Is Falling. -- Barrons.com

27 Oct 2025, 20:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Health Care Roundup: Market Talk

27 Oct 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

27 Oct 2025, 20:37 UTC

Earnings

Waste Management: Decrease From Prior Rev Expectations Is Primarily Related to Further Decline in Recycled Commodity Pricing, Modestly Lower Rev Expectations From Healthcare Solutions >WM

27 Oct 2025, 20:37 UTC

Earnings

Waste Management: 2025 Free Cash Flow Guidance Remains Between $2.8B and $2.9B >WM

27 Oct 2025, 20:37 UTC

Earnings

Waste Management: 2025 Total Co Rev Is Now Expected Approximately $25.275B >WM

27 Oct 2025, 20:37 UTC

Earnings

Waste Management: Affirming 2025 Adjusted Operating EBITDA Guidance Between $7.475B and $7.625B >WM

27 Oct 2025, 20:31 UTC

Earnings

Nucor Sees 4Q Earnings Lower Than 3Q

27 Oct 2025, 20:30 UTC

Earnings

Nucor 3Q Steel Mills Total Shipments 6.43M Tons >NUE

27 Oct 2025, 20:30 UTC

Earnings

Nucor 3Q EPS $2.63 >NUE

27 Oct 2025, 20:30 UTC

Earnings

Nucor 3Q Net $607M >NUE

27 Oct 2025, 20:30 UTC

Earnings

Nucor 3Q Sales $8.52B >NUE

27 Oct 2025, 20:30 UTC

Earnings

Nucor 3Q Total Tons Shipped to Outside Customers Down 1% >NUE

27 Oct 2025, 20:30 UTC

Earnings

Waste Management 3Q Adj EPS $1.98 >WM

27 Oct 2025, 20:30 UTC

Earnings

Waste Management 3Q Rev $6.44B >WM

27 Oct 2025, 20:30 UTC

Earnings

Waste Management 3Q Net $603M >WM

Peer Comparison

Price change

Day One Biopharmaceuticals Inc Forecast

Price Target

By TipRanks

220.43% upside

12 Months Forecast

Average 24 USD  220.43%

High 34 USD

Low 16 USD

Based on 9 Wall Street analysts offering 12 month price targets forDay One Biopharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

9 ratings

8

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

6.26 / 7.47Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

163 / 373 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
help-icon Live chat